Information Provided By: 
Fly News Breaks for January 30, 2020
XNCR
Jan 30, 2020 | 06:23 EDT
RBC Capital analyst Gregory Renza initiated coverage of Xencor with an Outperform rating and $44 price target. The analyst is positive on the "valuable potential" of the company's antibody technologies, which have been "validated" with multiple partnerships. Renze also sees Xencor's pipeline of antibodies having the potential to "generate best-in-class immuno-oncology treatment assets", anticipating long-term upside as the programs continue to advance.
News For XNCR From the Last 2 Days
There are no results for your query XNCR
